Characterization of a cell-adapted oncolytic virus

The efficacy of oncolytic viruses in cancer treatment depends on their ability to successfully infect and destroy tumor cells. In the manuscript by Elsner et al. (2024), the researchers adapt the oncolytic coxsackievirus B3 to colorectal cancer by serial passaging in the colorectal carcinoma cell line Colo320. After the 10th passage, they determine that there are 5 key mutations that have adapted the virus to the cancer. They engineer a new virus containing those 5 mutations plus a few others that keep the virus from replicating in non-cancerous cells. They then test both the original virus and the engineered virus in tumors in mice. Here, we fit a model to both data sets to estimate important characteristics and quantitatively compare to see what changed when the virus adapted.